WO2011161217A3 - Targeting of vegfr2 - Google Patents

Targeting of vegfr2 Download PDF

Info

Publication number
WO2011161217A3
WO2011161217A3 PCT/EP2011/060563 EP2011060563W WO2011161217A3 WO 2011161217 A3 WO2011161217 A3 WO 2011161217A3 EP 2011060563 W EP2011060563 W EP 2011060563W WO 2011161217 A3 WO2011161217 A3 WO 2011161217A3
Authority
WO
WIPO (PCT)
Prior art keywords
vegfr2
relates
present
cells
compounds
Prior art date
Application number
PCT/EP2011/060563
Other languages
French (fr)
Other versions
WO2011161217A2 (en
Inventor
Petra Hamerlik
Original Assignee
Palacký University in Olomouc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Palacký University in Olomouc filed Critical Palacký University in Olomouc
Publication of WO2011161217A2 publication Critical patent/WO2011161217A2/en
Publication of WO2011161217A3 publication Critical patent/WO2011161217A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Abstract

The present invention relates to the field of diagnosis and treatment of hyperproliferative diseases, such as cancer. In particular, the invention relates to methods of identifying and killing cancer stem-like cells and/or progenitor cells using compounds capable of associating with VEGFR2 and/or NRP-1. Furthermore, the invention relates to identification of compounds useful for identifying and killing cancer stem-like cells and/or progenitor cells, said compounds being VEGFR2 antagonists and/or NRP-1 antagonists. The present invention does also relate to identification of patients that are sensitive to VEGFR2 antagonist and hence would benefit from treatment according to the present invention
PCT/EP2011/060563 2010-06-23 2011-06-23 Targeting of vegfr2 WO2011161217A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201070288 2010-06-23
DKPA201070288 2010-06-23

Publications (2)

Publication Number Publication Date
WO2011161217A2 WO2011161217A2 (en) 2011-12-29
WO2011161217A3 true WO2011161217A3 (en) 2012-05-24

Family

ID=44628644

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/060563 WO2011161217A2 (en) 2010-06-23 2011-06-23 Targeting of vegfr2

Country Status (1)

Country Link
WO (1) WO2011161217A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2903692B1 (en) 2012-10-08 2019-12-25 St. Jude Children's Research Hospital Therapies based on control of regulatory t cell stability and function via a neuropilin-1:semaphorin axis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003068155A2 (en) * 2002-02-12 2003-08-21 Vanderbilt University Inhibition of vegf receptor signaling reverses tumor resistance to radiotherapy
WO2007056012A2 (en) * 2005-11-02 2007-05-18 Bayer Healthcare Llc Methods for prediction and prognosis of cancer, and monitoring cancer therapy
WO2008095015A2 (en) * 2007-01-30 2008-08-07 The General Hospital Corporation D/B/A Massachusetts General Hospital Method of treating recurrent tumors

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
US5700823A (en) 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
JPH105697A (en) 1996-06-20 1998-01-13 Seirei Ind Co Ltd Swinging apparatus for grain swinging and sorting apparatus
CO4950519A1 (en) 1997-02-13 2000-09-01 Novartis Ag PHTHALAZINES, PHARMACEUTICAL PREPARATIONS THAT UNDERSTAND THEM AND THE PROCESS FOR THEIR PREPARATION
US6563618B1 (en) 1997-12-23 2003-05-13 Texas Instruments Incorporated Post connection dual IRDA port power management
US6562618B1 (en) 1997-12-25 2003-05-13 Japan Tobacco, Inc. Monoclonal antibody against connective tissue growth factor and medicinal uses thereof
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
AU756838B2 (en) 1998-03-04 2003-01-23 Bristol-Myers Squibb Company Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors
HUP0103617A2 (en) 1998-05-29 2002-02-28 Sugen, Inc. Pyrrole substituted 2-indolinone protein kinase inhibitors, pharmaceutical compositions containing the compounds and their use
UA60365C2 (en) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Isothiazole derivatives, a method for preparing thereof, a pharmaceutical composition and a method for treatment of hyperproliferative disease of mammal
WO2000002871A1 (en) 1998-07-10 2000-01-20 Merck & Co., Inc. Novel angiogenesis inhibitors
AU760020B2 (en) 1998-08-31 2003-05-08 Merck & Co., Inc. Novel angiogenesis inhibitors
EP2298311B1 (en) 1999-01-13 2012-05-09 Bayer HealthCare LLC w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
DE60028740T2 (en) 1999-03-30 2007-05-24 Novartis Ag PHTHALAZINE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES
UA72946C2 (en) 1999-11-05 2005-05-16 Астразенека Аб Quinasoline derivatives as inhibitors of vascular endothelial growth factor (vegf)
WO2001037820A2 (en) 1999-11-24 2001-05-31 Sugen, Inc. Ionizable indolinone derivatives and their use as ptk ligands
US6515004B1 (en) 1999-12-15 2003-02-04 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
US6630500B2 (en) 2000-08-25 2003-10-07 Cephalon, Inc. Selected fused pyrrolocarbazoles
ATE430742T1 (en) 2000-12-21 2009-05-15 Smithkline Beecham Corp PYRIMIDINAMINES AS ANGIOGENESIS MODULATORS
US20020147198A1 (en) 2001-01-12 2002-10-10 Guoqing Chen Substituted arylamine derivatives and methods of use
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
US6878714B2 (en) 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
US7102009B2 (en) 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
US7307088B2 (en) 2002-07-09 2007-12-11 Amgen Inc. Substituted anthranilic amide derivatives and methods of use
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
EA011402B1 (en) 2004-01-23 2009-02-27 Эмджен Инк. Nitrogen-containing heterocyclic compounds and pharmaceutical use thereof
US7507748B2 (en) 2004-07-22 2009-03-24 Amgen Inc. Substituted aryl-amine derivatives and methods of use
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Substituted Amid derivatives & methods of use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003068155A2 (en) * 2002-02-12 2003-08-21 Vanderbilt University Inhibition of vegf receptor signaling reverses tumor resistance to radiotherapy
WO2007056012A2 (en) * 2005-11-02 2007-05-18 Bayer Healthcare Llc Methods for prediction and prognosis of cancer, and monitoring cancer therapy
WO2008095015A2 (en) * 2007-01-30 2008-08-07 The General Hospital Corporation D/B/A Massachusetts General Hospital Method of treating recurrent tumors

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BISCHOF M ET AL: "Triple combination of irradiation, chemotherapy (pemetrexed), and VEGFR inhibition (SU5416) in human endothelial and tumor cells", INTERNATIONAL JOURNAL OF RADIATION: ONCOLOGY BIOLOGY PHYSICS, PERGAMON PRESS, USA, vol. 60, no. 4, 15 November 2004 (2004-11-15), pages 1220 - 1232, XP004687773, ISSN: 0360-3016, DOI: 10.1016/J.IJROBP.2004.07.689 *
HEIKKI JOENSUU ET AL: "Amplification of genes encoding KIT, PDGFR.alpha. and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme", JOURNAL OF PATHOLOGY, JOHN WILEY & SONS LTD, GB, vol. 207, no. 2, 1 October 2005 (2005-10-01), pages 224 - 231, XP002658636, ISSN: 0022-3417, [retrieved on 20050715], DOI: 10.1002/PATH.1823 *
KNIZETOVA PETRA ET AL: "Autocrine regulation of glioblastoma cell cycle progression, viability and radioresistance through the VEGF-VEGFR2 (KDR) interplay", CELL CYCLE, vol. 7, no. 16, 15 August 2008 (2008-08-15), pages 2553 - 2561, XP002663336 *
KOZIN SERGEY V ET AL: "Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts", CANCER RESEARCH, vol. 61, no. 1, 1 January 2001 (2001-01-01), pages 39 - 44, XP002663335, ISSN: 0008-5472 *
WESTPHAL M ET AL: "Gliadel(R) wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial", ACTA NEUROCHIRURGICA ; THE EUROPEAN JOURNAL OF NEUROSURGERY, SPRINGER-VERLAG, VI, vol. 148, no. 3, 1 March 2006 (2006-03-01), pages 269 - 275, XP019377943, ISSN: 0942-0940, DOI: 10.1007/S00701-005-0707-Z *

Also Published As

Publication number Publication date
WO2011161217A2 (en) 2011-12-29

Similar Documents

Publication Publication Date Title
IN2014KN02933A (en)
CY1121742T1 (en) S100A4 ANTIBODIES AND THERAPEUTIC USES THEREOF
MX2021003858A (en) Conjugates for treating diseases caused by psma expressing cells.
NZ630542A (en) Methods of treating a tauopathy
NZ709059A (en) Immunotherapy with binding agents
MX355543B (en) Peptidomimetic macrocycles.
MX358517B (en) Methods for determining drug efficacy using cereblon-associated proteins.
MX353482B (en) METHODS FOR THE TREATMENT OF CANCER and INFLAMMATORY DISEASES USING CEREBLON AS A PREDICTOR.
WO2011141823A3 (en) Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists
WO2011113019A3 (en) Ctla4 proteins and their uses
IL231591A0 (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.
UA115231C2 (en) Imidazohyrrolidinone compounds
EP2582722A4 (en) Anti-gd2 antibodies
PH12014501844B1 (en) Peptidomimetic macrocycles
EA201500314A1 (en) DOSAGE FORMS OF ENZALUTAMIDE
EA201270722A1 (en) RIFAXIMINE FORMS AND THEIR APPLICATION
MX354481B (en) DKK1 ANTIBODIES and METHODS OF USE.
MX346500B (en) Methods and compositions for neural disease immunotherapy.
EA201590962A1 (en) NEW CONNECTIONS
TN2012000511A1 (en) Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
WO2013093115A3 (en) Marker sequences for breast cancer and the use thereof
WO2011106541A3 (en) Diagnostic methods involving loss of heterozygosity
EA201290744A1 (en) IMIDAZO [1,2-B] [1,2,4] TRIAZINS AS C-MET INHIBITORS
WO2013169631A3 (en) Wnt protein signalling inhibitors
WO2013109279A3 (en) Stabilization of the anti-cd20 antibody rituximab

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11733604

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11733604

Country of ref document: EP

Kind code of ref document: A2